Presentation is loading. Please wait.

Presentation is loading. Please wait.

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults  Eric L. Simpson, MD, MCR,

Published byGwendoline Booker Modified over 5 years ago

Similar presentations

Presentation on theme: "Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults  Eric L. Simpson, MD, MCR,"— Presentation transcript:

1 Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults  Eric L. Simpson, MD, MCR, Thomas Bieber, MD, Laurent Eckert, PhD, Richard Wu, PhD, Marius Ardeleanu, MD, Neil M.H. Graham, MD, Gianluca Pirozzi, MD, PhD, Vera Mastey, MSc  Journal of the American Academy of Dermatology  Volume 74, Issue 3, Pages (March 2016) DOI: /j.jaad Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Atopic dermatitis. Frequency (days per week) of non-itch skin symptoms evaluated on the Patient-Oriented Eczema Measure. ∗Percentages were calculated with N = 380 as the denominator. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Atopic dermatitis. Impact of itch and atopic dermatitis on sleep, assessed using items on the 5-dimension (5-D) Pruritus Scale and the Patient-Oriented Eczema Measure (POEM). ∗Percentages were calculated with N = 380 as the denominator. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 Atopic dermatitis. Impact of skin condition on items contributing to health-related quality of life as measured over the past week using the Dermatology Life Quality Index. ∗Impact of treatment was for therapies before randomization to treatment with dupilumab or placebo. †Percentages were calculated with N = 380 as the denominator. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

5 Fig 4 Atopic dermatitis. Patient-reported effects on outcomes contributing to health-related quality of life: functional and participatory activities assessed on the 5-D Pruritus Scale (N = 379) (A) and dimensions of the 5-dimension EuroQol (B). ∗Percentages were calculated with N = 380 as the denominator. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults  Eric L. Simpson, MD, MCR,"

Similar presentations

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 
Biphasic skin reactions during telaprevir-based therapy of Japanese patients infected with hepatitis C virus  Akiko Kishi, MD, Nobukazu Hayashi, MD, PhD,

Biphasic skin reactions during telaprevir-based therapy of Japanese patients infected with hepatitis C virus  Akiko Kishi, MD, Nobukazu Hayashi, MD, PhD,
Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Use of Eczema Action Plans (EAPs) to improve parental understanding of treatment regimens in pediatric atopic dermatitis (AD): A randomized controlled.

Use of Eczema Action Plans (EAPs) to improve parental understanding of treatment regimens in pediatric atopic dermatitis (AD): A randomized controlled.
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
Serum leptin and adiponectin levels in atopic dermatitis (AD) and their relation to disease severity  Byeol Han, MD, Wen Hao Wu, PhD, Jung Min Bae, MD,

Serum leptin and adiponectin levels in atopic dermatitis (AD) and their relation to disease severity  Byeol Han, MD, Wen Hao Wu, PhD, Jung Min Bae, MD,
Sarah Sung, MD, Alexa B. Kimball, MD, MPH 

Sarah Sung, MD, Alexa B. Kimball, MD, MPH 
Shawn G. Kwatra, BS, Hong Liang Tey, MRCP (UK), Saba M

Shawn G. Kwatra, BS, Hong Liang Tey, MRCP (UK), Saba M
Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002  Irwin B. Horwitz, PhD, Brian P. McCall,

Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002  Irwin B. Horwitz, PhD, Brian P. McCall,
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.
Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,
Ana Corcimaru, BS, Dean S. Morrell, MD, Craig N. Burkhart, MD 

Ana Corcimaru, BS, Dean S. Morrell, MD, Craig N. Burkhart, MD 
Alopecia areata after dupilumab for atopic dermatitis

Alopecia areata after dupilumab for atopic dermatitis
Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot.

Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot.

Similar presentations

Ads by Google